Novo Nordisk's Wegovy Pill Surpasses Three Million U.S. Prescriptions in Five Months

Novo Nordisk's Wegovy weight-loss pill has achieved a remarkable milestone, surpassing three million prescriptions in the United States just five months after its market introduction. The company announced Sunday that this rapid uptake marks "one of the strongest U.S. drug launches ever measured by volume."

Launched in the U.S. on January 5, the pill has seen a "very strong reception," according to Søren Løntoft Hansen, a senior analyst at Sydbank who closely follows Novo Nordisk. He noted that the prescription numbers place the launch "in the very top league" for drug introductions.

“

As Novo also writes itself, it is one of the best launches of pharmaceuticals ever. Measured by the number of prescriptions, it is the very top league.

Significantly, Novo Nordisk reports that most of these new prescriptions are going to individuals who have not previously used GLP-1 products, such as Wegovy or the diabetes medication Ozempic. This suggests the company is successfully expanding the market for these treatments, rather than simply shifting existing patients to a new formulation. The strong performance of the Wegovy pill was a key factor in Novo Nordisk raising its financial forecasts for the first quarter of the year, during which it generated 2.26 billion Danish kroner in sales.

“

Therefore, Novo is succeeding in expanding the market.